[Current view on the issue of insufficient effectiveness of anti-VEGF therapy for age-related macular degeneration]. / Sovremennyi vzglyad na problemu nedostatochnoi effektivnosti antiangiogennoi terapii vozrastnoi makulyarnoi degeneratsii.

Due to the significant medical and social importance of neovascular (wet) age-related macular degeneration (wAMD), increasing the effectiveness of anti-VEGF therapy used to treat this disease is one of the high-priority problems in modern retinology. This article focuses on pathobiological aspects and clinical manifestations of incomplete responses to anti-VEGF therapy of wAMD, considers the proposed ways to improve the terminology and classification of responses to therapy, as well as the assessment of its correctness and effectiveness of the treatment. It also discusses the available ways to optimize anti-VEGF therapy and define the criteria of its termination in cases when the treatment proves to be futile.

[Anti-VEGF therapy for neovascular age-related macular degeneration: causes of incomplete response]. / Anti-VEGF-terapiya neovaskulyarnoi vozrastnoi makulyarnoi degeneratsii: prichiny nedostatochnoi effektivnosti.

Neovascular age-related macular degeneration (nAMD) is one of the leading causes of decreased vision in the elderly population in many countries, including Russia. Anti-VEGF therapy is undoubtedly the «gold standard¼ of treatment for the disease, but its use in different patients is known to produce results with significant interindividual differences. This article reviews modern ideas about the clinical assessment of the degree of response to anti-VEGF therapy, possible reasons for its insufficient effectiveness (clinical, pharmacological, or related to nAMD pathogenesis), discusses the potential applications of the existing therapeutic strategies, and considers the prospects for the emergence of new strategies that could be used for solving that problem.

[Betahistine in vestibular disorders: current concepts and perspectives]. / Sovremennye predstavleniya o roli betagistina v lechenii zabolevanii vestibulyarnoi sistemy.

The goal of this paper is to review the pharmacological profile of betahistine and evidence for using it in the treatment of common vestibular disorders. Betahistine is a weak agonist for histamine H1 receptors and strong antagonist for histamine H3 receptors. It demonstrates the maximum benefit in different types of peripheral vertigo, especially in Meniere's disease. The best results in decreasing intensity of vertigo, frequency of attacks and stimulation of vestibular compensation were obtained in daily dose 48 mg during 3 months. In benign paroxysmal positional vertigo betahistine is used to treat residual dizziness after successful treatment of otolithiasis and to reduce the severity of vertigo during repositioning maneuvers. In vestibular neuritis betahistine stimulates central compensation during vestibular rehabilitation. A new once-daily drug formulation of modified-release betahistine is non-inferior to traditional and has a comparable safety profile, and could improve patient adherence. The implication of betahistine in the treatment of central vestibular disorders is under-researched. The efficacy of betahistine in increasing of vestibular compensation in post-stroke central vestibular disorders, persistent postural-perceptual dizziness and its role in vestibular migraine need further investigation.

[Age-related macular degeneration and diabetic eye lesion. Socio-economic aspects]. / Vozrastnaya makulyarnaya degeneratsiya i diabeticheskoe porazhenie glaz. Sotsial'no-ekonomicheskie aspekty zabolevaemosti.

Diabetic retinopathy (DR) and age-related macular degeneration (AMD) comprise a significant socio-medical problem for Russia. The article presents an analysis aimed at identifying the prerequisites for further research on the socio-economic consequences of retinal pathology. Studying the epidemiological aspects of DR and AMD, as well as the conditions for receiving medical aid helped define the main approaches to assessing the economic burden of retinal diseases in Russia. It also revealed the problems associated with completeness of registration and accounting of patients, the disparity between the volume of medical aid required and funding, and between the required and provided assistance for patients with these pathologies in clinical practice. Analysis of the disease cost will allow not only to determine the socio-economic consequences of retinal diseases, but also to find further directions for improving the quality of medical care for patients with DR and AMD in order to reduce its economic cost for the state and society. Evidently, there is a need for comprehensive assessment of the total burden of retinal diseases in Russia that would serve as a basis for subsequent assessment of the economic effectiveness of prevention and treatment measures.

[Protocol of intravitreal drug delivery. Consensus of the Expert Counsil of Retina and Optic Nerve Diseases of the All-Russian Public Organasation «Association of Ophthalmologists¼]. / Protokol vypolneniya intravitreal'nogo vvedeniya lekarstvennykh preparatov. Konsensus Ekspertnogo soveta po zabolevaniyam setchatki i zritel'nogo nerva Obshcherossiiskoi obshchestvennoi organizatsii «Assotsiatsiya vrachei-oftal'mologov¼.

Intravitreal drug administration is a procedure that has become widespread in modern ophthalmology. However, there is no global consensus on certain aspects of this manipulation, and practitioners feel the need for guidelines. In the Russian Federation, until now, such a document was not available. The expert council on diseases of the retina and optic nerve of All-Russian public organization «Association of Ophthalmologists¼, with participation of invited specialists, has studied and analyzed the existing foreign guidelines for performing intravitreal injections, as well as the regulatory framework in Russia. As a result, this Protocol was developed and approved for use in the healthcare system of the Russian Federation. The document regulates the requirements for specialists and organizations, the conditions for performing the procedure and the necessary material resources and presents an algorithm for performing intravitreal drug administration, a patient examination check-list for various conditions of the procedure, as well as parameters for evaluating and monitoring the quality of the procedure.

[Possibilities of multicolor confocal scanning laser ophthalmoscopy in complex diagnostics of severe proliferative diabetic retinopathy]. / Lazernaia mul'tikolor-oftal'moskopiia v kompleksnoi diagnostike tiazheloi proliferativnoi diabeticheskoi retinopatii.

Multicolor scanning laser ophthalmoscopy (multicolor SLO) is a new informative method of eye fundus visualization. The method is based on synchronously obtaining three separate confocal images with monochromatic laser sources - blue (488 nm), green (515 nm) and infrared (820 nm), which are then combined into one in the Multicolor mode. PURPOSE: To evaluate the informative value of multicolor SLO in a complex examination of patients with severe proliferative diabetic retinopathy (PDR). MATERIAL AND METHODS: A total of 46 patients (62 eyes) aged 19 to 75 years with severe PDR was examined. All patients had massive growth of proliferative tissue on the eye fundus, which caused traction deformation and/or retinal detachment in the posterior pole. Optical mediums of the eyes were sufficiently transparent to obtain high quality images. All patients underwent color photo-registration of the fundus, fluorescein angiography (FA), optical coherence tomography (OCT) and multicolor SLO under drug-induced mydriasis. RESULTS: Pseudo-volumetric images obtained with multicolor SLO allow visualization of of preretinal proliferative membranes and their structure, the degree of their vascularization, the anatomical features of their attachment to retina, and the occluded vessels on fundus periphery. Being an additional option on scanning laser ophthalmoscope, the technique does not require special equipment, which enables several separate examinations, including OCT and FA, to be performed on a single device. CONCLUSION: Multicolor SLO is a promising new method of visualizing structures of the eye fundus and can be successfully used in complex diagnostics, monitoring and preoperative preparation of patients with severe PDR.